GlassScriptPhysician profile
Wendell D Bronson
NPI 1205866688
$6,994.65
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $998 · 2021: $1,225 · 2022: $1,646 · 2023: $1,189 · 2024: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.16 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,897.16 | 2019-2024 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $907.36 | 2019-2023 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $843.11 | 2019-2024 | Rinvoq, Skyrizi |
| Pfizer INC. | $732.06 | 2019-2024 | |
| Ucb, INC. | $632.34 | 2019-2023 | Cimzia |
| Glaxosmithkline, LLC. | $584.08 | 2019-2024 | Benlysta |
| Novartis Pharmaceuticals Corporation | $395.77 | 2019-2024 | |
| Genentech USA, INC. | $306.90 | 2022-2023 | Actemra |
| Lilly USA, LLC | $276.54 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $82.61 | 2022-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $77.48 | 2019-2022 | |
| Tersera Therapeutics LLC | $54.76 | 2019 | |
| Celgene Corporation | $50.77 | 2019 | |
| Radius Health, INC. | $28.45 | 2023 | |
| Antares Pharma, INC. | $23.96 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Fresenius Kabi USA, LLC | $15.88 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $15.82 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.11 | 2019 | |
| Horizon Therapeutics Plc | $13.34 | 2019 | |
| Merck Sharp & Dohme LLC | $11.96 | 2019 | |
| Genzyme Corporation | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendell Bronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.